I

    Indaptus Therapeutics Inc (INDP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.15
    +0.01 (+0.44%)

    Market Cap: $151.90M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(21/38)
    Avg Surprise
    -38.11%

    Upcoming Estimates

    Mar 31, 2026
    EPS Consensus$-1.87
    Range$-1.87 - $-1.87
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-4.37-133.7%
    60d ago$-4.37-133.7%
    30d ago$-4.37-133.7%
    7d ago$-4.37-133.7%
    Current$-1.87
    Revenue Consensus
    $0
    Range$0 - $0
    0 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Mar 26EST
    		-$-1.87---
    Jun 26
    		$-0.02N/AN/ABeat+99.8%
    Dec 25
    		$-9.19$-4.36-110.78%Miss-2383.8%
    Sep 25
    		$-2.98$-4.17+28.54%Beat+66.7%
    Jun 25
    		$-9.09$-9.24+1.62%Beat+30.9%
    Mar 25
    		$-8.96$-5.04-77.78%Miss+28.9%
    Dec 24
    		$-0.37$-0.47+21.28%Beat+22.9%
    Sep 24
    		$-8.96$-13.16+31.91%Beat+31.9%
    Jun 24
    		$-13.16$-15.40+14.55%Beat-20.5%
    Mar 24
    		$-12.60$-15.96+21.05%Beat-2370.6%
    Dec 23
    		$-0.48$-0.54+11.11%Beat+96.1%
    Sep 23
    		$-13.16$-14.56+9.62%Beat-11.9%
    Jun 23
    		$-10.92$-16.24+32.76%Beat+15.2%
    Mar 23
    		$-0.51$-0.59+13.56%Beat-24.4%
    Dec 22
    		$-12.32$-14.56+15.38%Beat-100.0%
    Sep 22
    		$-11.76$-14.28+17.65%Beat+48.1%
    Jun 22
    		$-12.88$-12.04-6.98%Miss-132.9%
    Mar 22
    		$-0.41N/A+50.60%Beat+89.3%
    Dec 21
    		$-6.16N/A+63.33%Beat-190.6%
    Sep 21
    		$-22.68$-15.40-47.27%Miss-496.8%
    Jun 21
    		$-5.53$-2.56-116.02%Miss-38.3%
    Mar 21
    		$-3.84$-3.48-10.34%Miss+40.0%
    Dec 20
    		$-2.12$-3.40+37.65%Beat+85.3%
    Sep 20
    		$-3.80$-3.47-9.51%Miss+85.2%
    Jun 20
    		$-4.00$-4.27+6.32%Beat+83.3%
    Mar 20
    		$-6.40$-6.13-4.40%Miss+75.0%
    Dec 19
    		$-14.40$-12.00-20.00%Miss+51.4%
    Sep 19
    		$-25.60$-17.40-47.13%Miss-14.3%
    Jun 19
    		$-24.00$-24.16+0.66%Beat+11.8%
    Mar 19
    		$-25.60$-29.40+12.93%Beat+22.0%
    Dec 18
    		$-29.60$-24.16-22.52%Miss+2.6%
    Sep 18
    		$-22.40$-24.96+10.26%Beat+30.0%
    Jun 18
    		$-27.20$-26.08-4.29%Miss+27.7%
    Mar 18
    		$-32.80$-22.67-44.68%Miss-28.1%
    Dec 17
    		$-30.40$-22.00-38.18%Miss-
    Sep 17
    		$-32.00$-27.20-17.65%Miss-644.2%
    Jun 17
    		$-37.60$-24.80-51.61%Miss-
    Mar 17
    		$-25.60$-29.60+13.51%Beat-
    Dec 16
    		$0.00N/A+100.00%Beat-
    Sep 16
    		$-4.30$-0.30-1333.33%Miss-

    Key Metrics

    Valuation
    P/E Ratio-0.05EV/EBITDA1.03x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-318.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio19.48xQuick Ratio19.48x
    Trading Statistics
    Beta1.18Avg Volume829.48K
    52-Week High$6.6552-Week Low$0.92

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.14
    SMA 20$1.15
    SMA 50$2.03
    SMA 200$2.22
    EMA 10$1.16
    EMA 20$1.28
    EMA 50$1.73
    EMA 200$3.17

    MACD

    Line: -0.22Signal: -0.28Hist: 0.06

    ADX

    ADX: 17.7+DI: 25.6-DI: 21.6

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down64.0
    PSAR$1.07

    Bollinger Bands

    Upper Band$1.41
    Lower Band$0.90
    %B Position4438%(Upper)
    Band Width0.49

    RSI (14-Day)

    Neutral
    39.6

    Momentum Oscillators

    Stoch %K34.6
    Stoch %D33.7
    Williams %R-65.9
    ROC (10d)14.5%
    Momentum0.14
    CCI (20d)-23.7
    MFI (14d)87.4

    Volatility Measures

    ATR (14d)$0.20(17.9%)
    StdDev (20d)0.13
    Hist Vol192.1%(High)

    Volume Flow

    VWAP$1.14
    OBV445.3M
    AD Line56.5B
    CMF (20d)0.402

    Volume Metrics

    Avg Vol (20d)867.2K
    Vol Ratio0.2x(Low)
    VWMA (20d)$1.30

    Pivot Points

    R3$1.27
    R2$1.23
    R1$1.18
    Pivot Point$1.14
    S1$1.10
    S2$1.06
    S3$1.01

    Advanced Oscillators

    TSI-27.01
    Ultimate Osc36.2
    KST-383.68

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$1,470$0$0$0$1,928$0
    Cost of Revenue$0$0N/A$0$0$0$-735$0$0$0$320$0
    Gross Profit$0$0N/A$0$0$0$735$0$0$0$1,608$0
    Operating Expenses$1.81M$2.16M$8.16M$2.65M$4.46M$4.57M$4.17M$3.14M$4.11M$3.94M$4.18M$4.25M
    R&D$363,127$491,134$2.85M$1.52M$2.17M$2.81M$2.48M$1.47M$1.71M$1.59M$2.03M$2.23M
    SG&A$1.45M$1.67M$5.31M$1.13M$2.29M$1.76M$1.69M$1.68M$2.39M$2.35M$2.15M$2.02M
    Operating Income$-1,808,866$-2,159,588$-8,155,704$-2,648,487$-4,456,763$-4,572,559$-4,171,570$-3,142,057$-4,108,885$-3,943,239$-4,179,634$-4,248,412
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$381,482$40,129$365,718$787,703$0$230,180$0$0$0$0$0
    Income Before Tax$-1,808,866$-2,541,070$-8,195,833$-3,014,205$-5,244,466$-4,532,430$-4,401,750$-3,142,057$-4,015,267$-3,806,677$-4,002,780$-3,922,388
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-1,794,863$-2,541,070$-8,112,450$-2,975,117$-5,228,919$-4,532,430$-4,131,047$-3,069,036$-4,015,267$-3,806,677$-4,002,780$-3,922,388
    EBITDA$-1,808,866$-2,541,070$-8,195,833$-3,014,205$-5,244,466$-4,532,430$-4,401,750$-3,142,057$-4,015,267$-3,805,942$-4,002,460$-3,922,067
    EBIT$-1,808,866$-2,541,070$-8,195,833$-3,014,205$-5,244,466$-4,532,430$-4,401,750$-3,142,057$-4,015,267$-3,806,677$-4,002,780$-3,922,388
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about INDP

    News

    Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Declines By 64.1%

    Short interest in Indaptus Therapeutics (NASDAQ:INDP) dramatically decreased by 64.1% in July, totaling 93,141 shares as of July 31st. Despite beating consensus EPS estimates for the quarter, the stock trades near its one-year low, and analyst sentiment remains negative with an average "Sell" rating. Institutional ownership stands at 7.06%, with Virtu Financial LLC recently acquiring a new position.

    MarketBeat•8/14/26•
    Neutral

    Indaptus Therapeutics Releases Q2 2026 Financial Results

    Indaptus Therapeutics (INDP) reported its Q2 2026 financial results, with a basic and diluted EPS of -$0.02, which represents a significant narrowing of losses compared to Q2 2025. The biotechnology company posted a net loss of $1.8 million for the quarter. Analyst consensus for INDP currently shows 4 buy ratings, 1 hold, and 0 sell.

    AlphaStreet•8/13/26•
    Somewhat-Bearish

    Indaptus Therapeutics (Nasdaq: INDP) cuts losses and raises $12M in Q2

    Indaptus Therapeutics (INDP) significantly reduced its net loss in Q2 2026 to $1.8 million from $5.2 million in the previous year, primarily due to an 83% cut in R&D and a 37% decline in G&A expenses as it halted its Decoy20 clinical program and scaled back operations. The company also raised $12 million through a private placement of common shares and converted preferred stock, bolstering its liquidity to fund operations through Q2 2027. Despite these improvements, management expressed substantial doubt about its ability to continue as a going concern due to ongoing losses and strategic uncertainties.

    Stock Titan•8/13/26•
    Bearish

    Indaptus Therapeutics, Inc. 2Q 2026: Net loss $(1.79M), EPS $(0.02) — 10-Q Summary

    Indaptus Therapeutics, Inc. reported a significant improvement in its financial results for the second quarter of 2026, with a net loss of $(1.79M) and EPS of $(0.02), primarily due to reduced R&D and G&A spending following the wind-down of its Decoy20 Phase 1 study. The company is now evaluating strategic alternatives, including potential acquisitions or investments, and expects its current liquidity to fund operations through Q2 2027.

    TradingView•8/13/26•
    Neutral

    Indaptus Therapeutics (INDP) slashes R&D costs and bolsters cash after $12M raise

    Indaptus Therapeutics (INDP) significantly reduced its operating expenses and net loss in Q2 2026, bolstering its cash reserves with a $12 million private placement. The company reported an 83% drop in R&D costs and a narrowed net loss of $1.8 million, while it evaluates strategic alternatives for its Decoy immunotherapy platform and broader operations. Despite strengthening its balance sheet, the company disclosed substantial doubt about its ability to continue as a going concern, highlighting the need for additional capital.

    Stock Titan•8/13/26•
    Neutral

    Frequently Asked Questions About INDP

    Does INDP pay dividends?
    Indaptus Therapeutics Inc (INDP) does not currently pay a regular dividend.
    What is INDP's market cap?
    Indaptus Therapeutics Inc (INDP) has a market capitalization of $151.90M with a current stock price of $1.15.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In